BridgeBio Pharma (BBIO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
144.4mn → 191.5mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
+17.6% YoY in FY25 · 0.2% of revenue.
$46.1M returned vs $−447.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-144¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Over this window: gross 95.5% → 95.8%. Net margin -144.4% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 945,540.0 | 502,076.0 | 221,902.0 | 9,303.0 | 77,648.0 | 69,716.0 | ▲126.3% | +63.8% |
Cost of revenue | 53,542.0 | 20,962.0 | 3,878.0 | 2,446.0 | 3,434.0 | 3,114.0 | ▲440.5% | +61.1% |
Gross profit | 891,998.0 | 481,114.0 | 218,024.0 | 6,857.0 | 74,214.0 | 66,602.0 | ▲120.7% | +63.9% |
Research & development | 536,007.0 | 451,953.0 | 506,461.0 | 455,711.0 | 399,462.0 | 451,024.0 | ▼10.8% | +0.1% |
Selling, general & admin | 709,096.0 | 531,225.0 | 288,931.0 | 150,590.0 | 143,189.0 | 192,210.0 | ▲83.9% | +28.9% |
Total operating expenses | 1,256,234.0 | 1,004,525.0 | 810,997.0 | 614,227.0 | 586,416.0 | 643,234.0 | ▲23.9% | +11.8% |
Operating incomefeeds ROC rank | −364,236.0 | −523,411.0 | −592,973.0 | −607,370.0 | −512,202.0 | −576,632.0 | ▲11.7% | — |
Other income, net | −212,232.0 | −209,092.0 | 50,779.0 | −45,881.0 | 27,550.0 | −9,822.0 | — | — |
Pretax income | −576,468.0 | −732,503.0 | −542,194.0 | −653,251.0 | −484,652.0 | −586,454.0 | ▼35.1% | — |
Income tax | — | 435.0 | 1,153.0 | 0.0 | 0.0 | — | ▼62.3% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −565,832.0 | −724,931.0 | −535,762.0 | −643,202.0 | −481,183.0 | −586,454.0 | ▼35.3% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −3.04 | −3.78 | −2.88 | −3.95 | −3.26 | −3.90 | ▼31.3% | — |
Diluted shares (mn) | 196.03 | 191.53 | 186.08 | 162.79 | 147.47 | 144.36 | ▲2.9% | +7.3% |
| Margins | ||||||||
Gross margin92nd pct in Healthcare | 94.3% | 95.8% | 98.3% | 73.7% | 95.6% | 95.5% | ▼2.4pp | +0.3pp |
Operating margin | −38.5% | −104.2% | −267.2% | −6528.8% | −659.6% | −827.1% | ▲163.0pp | +722.9pp |
Net margin13th pct in Healthcare | −59.8% | −144.4% | −241.4% | −6913.9% | −619.7% | −841.2% | ▲97.1pp | +696.8pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was BridgeBio Pharma's revenue last fiscal year?
BridgeBio Pharma reported revenue of $502.1M in fiscal 2025, up 126.3% from fiscal 2024.
What was BridgeBio Pharma's net income?
BridgeBio Pharma reported net income of −$724.9M in fiscal 2025, a net margin of −144.4%.

